Data / Drug companies / Sda Laboratories, Inc.
Sda Laboratories, Inc.: 8 products in the FDA NDC directory, labeler code 66424
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sda Laboratories, Inc. (labeler code 66424) lists 8 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 8 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on July 1, 2025.
The request: Watch Sda Laboratories, Inc. (FDA labeler code 66424): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 66424
- Products in commercial distribution
- 8
- Packages
- 11
- Finished drugs by generic name
- 6
- Prescription products
- 0
- Over the counter products
- 8
- Flagged as original packager
- 8 of 8 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 27, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 7 | 87.5% |
| Generic drugs (ANDA) | 1 | 12.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 8 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Diphenhydramine hcl | 2 | 99 |
| Guaifenesin | 2 | 123 |
| Bisacodyl | 1 | 60 |
| Dextromethorphan hbr, guaifenesin | 1 | 67 |
| Cetirizine hydrochloride | 1 | 119 |
| Sennosides a and b | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 3 | 37.5% |
| Capsule | 2 | 25% |
| Liquid | 2 | 25% |
| Syrup | 1 | 12.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Histamine-1 Receptor Antagonist | 3 |
| Expectorant | 3 |
| Stimulant Laxative | 1 |
| Sigma-1 Agonist | 1 |
| Uncompetitive N-methyl-D-aspartate Receptor Antagonist | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Stimulant Laxative Enteric Coated | 66424-002 | Tablet | Over the counter monograph drugs | July 1, 2025 |
| Mucus relief | 66424-001 | Tablet | Over the counter monograph drugs | July 1, 2025 |
| SDA Laboratories Tussin DM | 66424-565 | Liquid | Over the counter monograph drugs | December 1, 2024 |
| SDA Laboratories Tussin | 66424-563 | Liquid | Over the counter monograph drugs | December 1, 2024 |
| Cetirizine hydrochloride 10 mg | 66424-564 | Tablet | Generic drugs (ANDA) | April 27, 2021 |
| SENNA Syrup | 66424-562 | Syrup | Over the counter monograph drugs | January 1, 2015 |
| Diphenhydramine HCL | 66424-021 | Capsule | Over the counter monograph drugs | January 27, 2010 |
| Diphenhydramine HCL | 66424-020 | Capsule | Over the counter monograph drugs | January 27, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.